Endocrine-signaling research
CJC-1295 / Ipamorelin
Lyophilized endocrine-signaling research peptide for systems review
CJC-1295 / Ipamorelin combines a GHRH analog research peptide with a selective ghrelin receptor secretagogue reference, creating a GH-axis research stack.
Support can confirm any currently available COAs or batch documentation for this product.
Request available documentsConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesFor laboratory research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, mitigate, or prevent disease.
Keep sealed, cold, dry, and protected from heat swings. Confirm product-specific storage on arrival.
Packed for transit stability with order support available for warm-weather routes.
Batch-linked certificate support is available through the documentation desk.
Araştırma bağlamı
CJC-1295 / Ipamorelin araştırma profili
CJC-1295 / Ipamorelin combines two distinct GH-axis research approaches. The CJC component is a growth hormone-releasing hormone analog that acts at the GHRH receptor, while ipamorelin is a ghrelin-receptor secretagogue studied at GHS-R. Research commonly examines whether these complementary upstream signals alter GH-release patterns, IGF-1 markers, receptor selectivity, pharmacokinetics, or endocrine feedback differently from either component alone. The exact CJC form matters because DAC-modified and non-DAC analogs have different duration profiles, so the listed identity and batch documentation should be checked. Component studies provide useful context but do not establish the behavior or synergy of a combined catalog product.
Önerilen mekanizma
Combines GHRH-receptor agonism from the CJC component with GHS-R1a agonism from ipamorelin. Both converge on pituitary growth-hormone release through different upstream receptors, creating a proposed complementary secretagogue model.
Çalışmalarda bildirilen etkiler
- CJC-1295 with DAC studies reported prolonged increases in circulating GH and IGF-1 in healthy-adult pharmacology studies.
- Ipamorelin studies reported dose-related GH release with a selectivity profile different from older GHRP compounds.
- The combination itself lacks strong independent evidence demonstrating synergy, a predictable pulse pattern, or improved outcomes over the separate components.
Yaygın araştırma sonlanım noktaları
Exact CJC identity and DAC status, GHRH receptor response, GHS-R response, GH pulse amplitude and duration, IGF-1, ACTH, cortisol, prolactin, pharmacokinetics, and component controls.
Kanıtlar ve sınırlamalar
Human pharmacology exists for individual CJC-1295 and ipamorelin references. Blend-specific effects and equivalence to those study materials are not established.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
What documentation can I request before ordering?
Before ordering, contact support with the product name, selected format, andu2014if availableu2014an order or batch reference to request available batch-linked documentation.
What should I confirm before ordering?
Compare the product name, listed amount, physical form, storage note, price, and documentation route. When the order arrives, match the product and lot or batch reference to the order record and available documentation.